Effects of Liraglutide on Body Surface Gastric Mapping

You may not qualify if:

• Confirmed diagnosis of a comorbidity known to affect gastric motility (i.e., Parkinson\'s Disease, Type 1 or 2 Diabetes).
• Medications in the last 3 months known to impact gastric motility.
• Any Gastric Surgery
• Pregnancy or lactation, determined by pregnancy test at timeof enrolment.
• Known allergy to adhesives and/or skin sensitivities, or any allergy to liraglutide or any components of the liraglutide/Saxenda formulation, or known hypersensitivity to Spirulina, egg, milk or wheat allergens
• Use of GLP-1 agonist and/or on regular insulin in the past 3months.
• History of gastroduodenal dysfunction and/or meets the ROME IV symptom criteria for a gastroduodenal disorder of gut-brain interaction (functional dyspepsia, chronic nausea and vomiting syndrome, cyclic vomiting syndrome, rumination syndrome, cannabinoid hyperemesis syndrome, or a belching disorder).
• History of peptic ulcer, pancreatitis, cholelithiasis, choledocholithiasis, History of kidney or hepatic dysfunction
• History of psychiatric disturbance requiring medication in the year before enrolment, any history of suicide attempt or eating disorder
• History of Type II Diabetes or glucose intolerance (treated or untreated)
• History of cancer other than basal cell skin cancer, and patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of angioedema or urticaria disorder
• History of cardiac disorder or arrhythmia
• Any tobacco, vaping or cannabinoid use in the 30 days prior to study